Keros Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Keros Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $287.42 million for the year ending 2025.

  • Keros Therapeutics, Inc. showed a decrease of -48.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Keros Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
  • XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 7 years of available data (2019 to 2025), Keros Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 3,994.2%.
  • Historical annual values: Fiscal year 2025: $287.42 million | Fiscal year 2024: $559.93 million | Fiscal year 2023: $331.15 million | Fiscal year 2022: $279.05 million | Fiscal year 2021: $230.04 million | Fiscal year 2020: $265.88 million | Fiscal year 2019: $7.02 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: